Tag: adalimumab

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Adalimumab, Infliximab and Etanercept Biosimilars Market Size Forecast: How Big Could The Market Get By 2030?

The adalimumab, infliximab and etanercept biosimilars market size has experienced rapid expansion in recent years. This market is projected to expand from $4.96 billion in 2025 to $5.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by factors such as the increasing prevalence of autoimmune diseases, the high expense of originator biologics, rising recognition of biosimilars, advancements in biologics manufacturing processes, and favorable government policies.

The adalimumab, infliximab, and etanercept biosimilars market is anticipated to experience rapid expansion over the next few years. It is projected to grow to $8.05 billion in 2030, achieving a compound annual growth rate (CAGR) of 10.1%. This expected growth during the forecast period can be attributed to several factors, including advancements in precision medicine, the expansion of biosimilar pipelines, rising healthcare expenditure, increasing adoption of digital health solutions, and a growing geriatric population. Major trends foreseen in this period include enhanced biosimilar adoption and market penetration, the development of cost-effective TNF-alpha inhibitors, supportive regulatory approvals and policy frameworks, the expansion of hospital and retail pharmacy networks, and the implementation of personalized treatment protocols.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Catalysts And Demand Drivers

The increasing occurrence of autoimmune diseases is projected to stimulate the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the coming years. Autoimmune disease refers to health conditions or disorders resulting from immune system dysfunction, where the body’s immune cells attack its own healthy cells. Adalimumab, infliximab, and etanercept are biological drugs containing tumor necrosis factor (TNF) alpha inhibitors, utilized for treating various autoimmune diseases. For instance, in 2023, according to Johns Hopkins University, a US-based private research university, around 10 million people in the US, representing 3% of the population, were affected by all autoimmune illnesses. Therefore, the rising prevalence of autoimmune diseases is a significant driver for the growth of the adalimumab, infliximab, and etanercept biosimilars market.

Adalimumab, Infliximab and Etanercept Biosimilars Market Segment Analysis Spotlighting Growth Areas

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Adalimumab, Infliximab and Etanercept Biosimilars Market Trends Shaping Long-Term Demand

Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing technological advancements, such as high-concentration, citrate-free biosimilars, to meet the increasing demand for more patient-friendly formulations, enhanced affordability, and expanded market access. These advanced high-concentration, citrate-free versions possess the same therapeutic monoclonal antibody structure as traditional biosimilars but provide a more comfortable injection experience, with less sting on administration. This potentially improves patient adherence and switching rates compared to conventional buffered formulations. As an illustration, in June 2023, Celltrion USA, a US-based biopharmaceutical company, launched Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), developed to deliver identical potency and efficacy in a more patient-friendly format. Yuflyma offers the full therapeutic effect of adalimumab, with the added benefit of improved tolerability due to reduced injection pain, fostering broader uptake in the immunology market, particularly for chronic inflammatory diseases.

Adalimumab, Infliximab and Etanercept Biosimilars Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

View The Full Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Adalimumab, Infliximab and Etanercept Biosimilars Market Leading Geography: Which Region Contributes The Most Revenue?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Adalimumab, Infliximab and Etanercept Biosimilars Market Revenue Growth Supported By A CAGR Of 8.04% Through 2030

The market for biosimilars of adalimumab, infliximab, and etanercept has seen swift expansion in recent years. Projected figures indicate a rise from $4.96 billion in 2025 to $5.47 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. This historical upward trend is driven by several factors, including a higher incidence of autoimmune conditions, the substantial expense associated with original biologic drugs, enhanced awareness surrounding biosimilars, advances in the production of biologics, and favorable policies implemented by governments.

Over the next several years, the market for adalimumab, infliximab, and etanercept biosimilars is anticipated to experience robust expansion. Projections indicate it will reach $8.05 billion by 2030, achieving a compound annual growth rate (CAGR) of 10.1%. This expected growth is fueled by progress in precision medicine, an increasing number of biosimilar pipelines, higher healthcare spending, greater uptake of digital health tools, and a growing elderly population. Key developments shaping the forecast period involve wider biosimilar acceptance and market reach, economical TNF-alpha inhibitor creation, regulatory endorsements and supportive policies, expanded distribution through hospital and retail pharmacy channels, and the adoption of tailored treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Drivers: What Factors Are Accelerating Expansion?

The growth of the market for adalimumab, infliximab, and etanercept biosimilars is anticipated to be driven by the increasing incidence of autoimmune diseases. Autoimmune diseases are conditions resulting from immune system malfunction, where the body’s own healthy cells are attacked by immune cells. Adalimumab, infliximab, and etanercept are biological therapies that function as tumor necrosis factor (TNF) alpha inhibitors, commonly employed in the treatment of various autoimmune disorders. As an example, data from Johns Hopkins University, a private research institution based in the US, indicates that in 2023, approximately 10 million individuals in the United States—accounting for 3% of the population—are impacted by all forms of autoimmune diseases. Hence, the escalating prevalence of autoimmune diseases is fueling the expansion of the adalimumab, infliximab, and etanercept biosimilars market.

Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation Trends And Revenue Drivers

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Adalimumab, Infliximab and Etanercept Biosimilars Market Trends: What Is Shaping Future Industry Growth?

Leading firms in the adalimumab, infliximab, and etanercept biosimilars sector are prioritizing innovations like high-concentration, citrate-free biosimilars to address the growing need for patient-centric formulations, enhanced cost-effectiveness, and wider market accessibility. These advanced high-concentration, citrate-free products maintain the same therapeutic monoclonal antibody structure as standard biosimilars, yet deliver a more tolerable injection experience with less discomfort during administration, which can boost patient adherence and encourage switching from traditional buffered options. A notable example occurred in June 2023, when Celltrion USA, a US-based biopharmaceutical company, introduced Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab). This product is engineered to provide equivalent strength and effectiveness in a more convenient format for patients, offering the full therapeutic advantages of adalimumab while minimizing injection-related discomfort, thereby facilitating greater adoption in the immunology marketplace, especially for managing chronic inflammatory conditions.

Adalimumab, Infliximab and Etanercept Biosimilars Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Access The Complete Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Adalimumab, Infliximab and Etanercept Biosimilars Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Adalimumab, Infliximab and Etanercept Biosimilars Market During The Forecast Period?

The market size for adalimumab, infliximab, and etanercept biosimilars has shown rapid development in recent years. It is forecast to increase from $4.96 billion in 2025 to $5.47 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The expansion observed historically can be linked to the rising occurrence of autoimmune diseases, the substantial cost of originator biologics, growing understanding of biosimilars, enhancements in biologics manufacturing, and supportive governmental policies.

The adalimumab, infliximab and etanercept biosimilars market size is anticipated to undergo significant expansion over the coming years. It is projected to reach $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This expansion during the forecast period is propelled by factors such as advancements in precision medicine, the growing scope of biosimilar pipelines, increasing healthcare expenditure, wider adoption of digital health solutions, and an expanding geriatric population. Prominent trends expected in this timeframe encompass biosimilar adoption and market penetration, the development of cost-effective tnf-alpha inhibitors, favorable regulatory approvals and policy support, the expansion of hospital and retail pharmacy networks, and the implementation of personalized treatment protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Drivers Are Advancing The Adalimumab, Infliximab and Etanercept Biosimilars Market Growth?

The increasing occurrence of autoimmune conditions is anticipated to drive the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the future. An autoimmune disease is characterized by disorders or sicknesses resulting from an immune system malfunction, where immune cells target and attack the body’s own healthy cells. Adalimumab, infliximab, and etanercept are biological medications, specifically tumor necrosis factor (TNF) alpha inhibitors, employed in the treatment of diverse autoimmune ailments. As an illustration, data from Johns Hopkins University, a private research university located in the US, indicated that approximately 10 million individuals in the US, representing 3% of the populace, were impacted by autoimmune illnesses in 2023. Consequently, the growing frequency of autoimmune diseases is a key factor boosting the growth of the adalimumab, infliximab, and etanercept biosimilars market.

How Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Distributed Across Key Segments?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Which Trends Are Guiding The Development Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading companies operating within the adalimumab, infliximab, and etanercept biosimilars market are concentrating on technological improvements, such as high-concentration, citrate-free biosimilars, to address the growing demand for formulations that are easier for patients to use, more economical, and have wider market access. These advanced high-concentration, citrate-free versions provide the same therapeutic monoclonal antibody structure as traditional biosimilars but ensure a more comfortable injection experience, reducing the sting upon administration, which may lead to better adherence and higher switching rates compared to standard buffered formulations. For example, in June 2023, Celltrion USA, a US-based biopharmaceutical company, unveiled Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), engineered to offer equivalent potency and efficacy in a format more accommodating for patients. Yuflyma delivers the full therapeutic effect of adalimumab, with the added benefit of enhanced tolerability due to reduced injection pain, and promotes wider acceptance in the immunology market, especially for chronic inflammatory diseases.

Which Key Players Are Active In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Access The Complete Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Accounts For The Highest Share Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Adalimumab, Infliximab and Etanercept Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Expected To Reach Based On Its 2026 Value?

The market size for adalimumab, infliximab, and etanercept biosimilars has experienced rapid expansion in recent years. This market is projected to expand from $4.96 billion in 2025 to reach $5.47 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been influenced by factors such as the growing prevalence of autoimmune diseases, high cost of originator biologics, increasing awareness of biosimilars, improvements in biologics manufacturing, and supportive government regulations.

The market for adalimumab, infliximab, and etanercept biosimilars is projected to experience swift expansion over the coming years. This market is anticipated to reach a value of $8.05 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This projected growth during the forecast period is fueled by progress in precision medicine, the enlargement of biosimilar development pipelines, escalating healthcare spending, the increasing integration of digital health solutions, and an expanding elderly demographic. Key trends anticipated within this period encompass wider biosimilar adoption and market penetration, the creation of economical TNF-alpha inhibitors, supportive regulatory approvals and policies, an increase in hospital and retail pharmacy networks, and the implementation of personalized treatment approaches.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Significant Factors Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market Expansion?

The increasing occurrence of autoimmune conditions is projected to boost the adalimumab, infliximab, and etanercept biosimilars market going forward. Autoimmune disease refers to disorders caused by immune system dysfunction, where immune cells attack the body’s healthy cells. Adalimumab, infliximab, and etanercept are biological drugs functioning as tumor necrosis factor (TNF) alpha inhibitors, employed in treating various autoimmune diseases. For instance, in 2023, Johns Hopkins University, a US-based private research university, reported that approximately 10 million people in the US, accounting for 3% of the population, were affected by all autoimmune illnesses. Consequently, the rising prevalence of autoimmune diseases acts as a driver for the growth of the adalimumab, infliximab, and etanercept biosimilars market.

Which Segment Types Are Examined In The Adalimumab, Infliximab and Etanercept Biosimilars Market Segment Study?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

What Trends Are Affecting The Direction Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Companies active in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing technological innovations, such as developing high-concentration, citrate-free biosimilars. This focus aims to address the increasing need for formulations that are easier for patients, more affordable, and offer wider market availability. These advanced citrate-free, high-concentration products maintain the identical therapeutic monoclonal antibody structure as their traditional biosimilar counterparts, while providing a less painful injection (reduced stinging during administration). This improvement could lead to better patient compliance and higher conversion rates from standard buffered options. For example, in June 2023, Celltrion USA, a biopharmaceutical company based in the US, introduced Yuflyma (adalimumab-aaty). This product is a citrate-free, high-concentration (100 mg/mL) biosimilar to Humira (adalimumab), created to offer equivalent potency and efficacy in a more user-friendly format. Yuflyma delivers the complete therapeutic effect of adalimumab, enhanced by better tolerability due to less injection discomfort, thereby fostering wider adoption within the immunology market, particularly for chronic inflammatory conditions.

Which Players Are Part Of The Competitive Landscape Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Get The Full Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Leads The Adalimumab, Infliximab and Etanercept Biosimilars Market In Overall Market Size?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Adalimumab, Infliximab and Etanercept Biosimilars Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the adalimumab, infliximab and etanercept biosimilars market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Adalimumab, Infliximab and Etanercept Biosimilars Market?

The market for adalimumab, infliximab, and etanercept biosimilars has experienced significant expansion recently. This market is projected to expand from $4.96 billion in 2025 to $5.47 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. Historically, this growth has been driven by factors such as the increasing incidence of autoimmune diseases, the substantial cost of originator biologics, greater recognition of biosimilars, advancements in biologics manufacturing, and favorable government policies.

The adalimumab, infliximab and etanercept biosimilars market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $8.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.1%. This expansion over the forecast period is attributable to breakthroughs in precision medicine, the enlargement of biosimilar pipelines, increasing healthcare spending, the broader embrace of digital health technologies, and a growing older demographic. Significant trends for the forecast period include the increasing uptake and market presence of biosimilars, the development of economical TNF-alpha inhibitors, favorable regulatory approvals and policy backing, the enlargement of hospital and retail pharmacy infrastructures, and the implementation of customized treatment plans.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Drivers Are Supporting Technological Adoption In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The increasing occurrence of autoimmune diseases is anticipated to propel the expansion of the adalimumab, infliximab, and etanercept biosimilars market in the coming years. Autoimmune disease refers to conditions or disorders that arise from immune system dysfunction, where immune cells attack the body’s healthy cells. Adalimumab, infliximab, and etanercept are biological drugs, specifically tumor necrosis factor (TNF) alpha inhibitors, utilized for treating various autoimmune diseases. For instance, in 2023, Johns Hopkins University, a US-based private research university, reported that approximately 10 million people in the US, which accounts for 3% of the population, suffer from all autoimmune illnesses. Consequently, the rising prevalence of autoimmune diseases is a key driver for the growth of the adalimumab, infliximab, and etanercept biosimilars market.

Which Segments Are Contributing To The Growth Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Which Trends Are Influencing The Performance And Direction Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Companies operating within the adalimumab, infliximab, and etanercept biosimilars market are concentrating on technological innovations, such as high-concentration, citrate-free biosimilars, to satisfy the growing need for more patient-friendly formulations, greater affordability, and wider market access. These advanced versions provide the identical therapeutic monoclonal antibody structure as conventional biosimilars but with a more comfortable injection experience, causing less discomfort during administration, potentially boosting patient adherence and transition rates compared to standard buffered formulations. For instance, in June 2023, Celltrion USA, a US-based biopharmaceutical company, launched Yuflyma (adalimumab-aaty), a citrate-free, high-concentration (100 mg/mL) biosimilar of Humira (adalimumab), designed to offer the same potency and efficacy in a more convenient format for patients. Yuflyma delivers the complete therapeutic effect of adalimumab, with the added advantage of improved tolerability due to reduced injection pain, fostering broader adoption in the immunology market, particularly for chronic inflammatory diseases.

Who Are The Prominent Global Companies Shaping The Adalimumab, Infliximab and Etanercept Biosimilars Market Landscape?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market are Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Adalimumab, Infliximab and Etanercept Biosimilars Market?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2025. The regions covered in the adalimumab, infliximab and etanercept biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Adalimumab, Infliximab and Etanercept Biosimilars Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2026, By The Business Research Company

Adalimumab Infliximab And Etanercept Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilars-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the adalimumab, infliximab and etanercept biosimilars market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Adalimumab, Infliximab and Etanercept Biosimilars Market Be Worth By 2029, And What CAGR Will It Achieve?

The adalimumab, infliximab and etanercept biosimilars market size has experienced rapid expansion in recent years. This market is projected to grow from $4.37 billion in 2024 to $4.96 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.6%. The growth observed in the historic period is attributable to elements such as increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives, and rising healthcare costs.

The adalimumab, infliximab and etanercept biosimilars market is projected to experience substantial growth in the coming years. It is anticipated to reach $7.34 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.3%. This expansion during the forecast period is primarily driven by factors such as a rise in healthcare expenditure, an aging population, and increased access to healthcare. Furthermore, significant trends expected in the forecast period involve a concentrated effort on launching new products, engaging in mergers and acquisitions, establishing strategic partnerships, and increasing investments.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Factors Are Driving The Adalimumab, Infliximab and Etanercept Biosimilars Market Forward?

The ability of biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market stems from the patent expiration of branded drugs. For example, in the United States, following the patent expiry of the branded drug Remicade, the FDA gave its approval to Inflectra, developed by Hospira (a Pfizer Inc. company), for treating various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. Similarly, after Amgen’s Enbrel patent expired in the EU, Benepali (an Enbrel biosimilar) received approval from the European Commission. The patent for Humira also expired, leading to the availability of its biosimilars on the market. The FDA recently approved Hulio, which is the sixth biosimilar of Humira. Thus, the patent expiry of branded biologic drugs like Humira, Enbrel, and Remicade is expected to stimulate demand in the adalimumab, infliximab, and etanercept biosimilars market.

Which Segments Form The Key Structure Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

What Strategic Shifts And Innovations Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading companies in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on developing innovative products, such as citrate-free adalimumab, to provide reliable services to customers. Citrate-free adalimumab is a formulation of the biological medication adalimumab that does not contain citrate. For instance, in December 2022, Fresenius Kabi, a Germany-based manufacturer of medicines and technologies for infusion, transfusion, and clinical nutrition, announced the FDA approval for biosimilar Idacio (adalimumab) for use in the management of chronic autoimmune disorders for all permissible uses of the reference product. It has been developed utilizing advanced analytical methods for application in the treatment of several chronic conditions.

Which Firms Are Making The Biggest Impact In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Is Expected To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market In The Next Few Years?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2025, By The Business Research Company

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2025

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Trastuzumab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Adalimumab, Infliximab and Etanercept Biosimilars Market Covering 2025–2034?

The adalimumab, infliximab and etanercept biosimilars market has experienced rapid expansion in recent years. It is projected to grow from $4.37 billion in 2024 to $4.96 billion in 2025, at a compound annual growth rate (CAGR) of 13.6%. This historical growth can be attributed to increased healthcare expenditure, evolving regulatory landscapes, government initiatives, and rising healthcare costs.

The adalimumab, infliximab, and etanercept biosimilars market size is poised for significant expansion over the next few years. It is projected to increase to $7.34 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.3%. This growth during the forecast period is primarily attributable to rising healthcare expenditure, a demographic shift towards an aging population, and enhanced access to healthcare. Prominent trends anticipated in the forecast period encompass an emphasis on introducing new products, pursuing mergers and acquisitions, forging strategic partnerships, and boosting investment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

Which Factors And Drivers Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market In 2025?

The cessation of patent protection for branded drugs enables biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market. For instance, in the United States, the FDA granted approval to Inflectra, developed by Hospira (a Pfizer Inc. company), for treating various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, subsequent to the patent expiry of the branded drug Remicade. In a similar vein, Amgen’s Enbrel had its patent expire in the EU, and this expiration facilitated the European Commission’s approval of Benepali, a biosimilar of Enbrel. Furthermore, Humira’s patent lapsed, making its biosimilars available in the market, with the FDA recently approving Hulio, the sixth biosimilar of Humira. These instances collectively indicate that the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade will thus propel the demand within the adalimumab, infliximab, and etanercept biosimilars market.

What Are The Major Segments Identified In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Which Trends Are Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies active in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on developing innovative offerings, such as citrate-free adalimumab, to deliver reliable services to customers. Citrate-free adalimumab represents a version of the biological drug adalimumab that is formulated without citrate. For example, in December 2022, Fresenius Kabi, a Germany-based producer of pharmaceuticals and equipment for infusion, transfusion, and clinical nutrition, declared that its biosimilar Idacio (adalimumab) had received FDA approval for managing chronic autoimmune disorders across all authorized applications of the reference product. This product was developed utilizing advanced analytical techniques for its use in treating numerous chronic health issues.

Which Major Industry Participants Are Leading The Adalimumab, Infliximab and Etanercept Biosimilars Market Growth?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

What Are The Regional Market Dynamics Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Industry?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Adalimumab, Infliximab and Etanercept Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

Browse Through More Reports Similar to the Global Adalimumab, Infliximab and Etanercept Biosimilars Market 2025, By The Business Research Company

Oncology Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2025

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Trastuzumab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Adalimumab, Infliximab and Etanercept Biosimilars Market Today And What Is Its Future Size?

The market space for biosimilars including adalimumab, infliximab, and etanercept has expanded swiftly in the past few years. It is projected to surge from $4.37 billion in 2024 to $4.96 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.6%. The notable growth experienced in the historical period is the outcome of boosted healthcare spending, alterations in regulations, governmental initiatives, and escalating healthcare expenses.

The biosimilars market for adalimumab, infliximab, and etanercept is projected to exhibit speedy expansion in the near future, reaching a total market value of $7.34 billion in 2029 with a compound annual growth rate (CAGR) of 10.3%. This expected surge during the forecast period can be attributed to factors such as increased spending on healthcare, an ageing demographic, and improved access to healthcare facilities driving the market’s growth. The predominant trends anticipated within this forecast span include the emphasis on the launch of new products, concentration on mergers and acquisitions, prioritising strategic collaborations, and augmenting investments.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Growth-Enabling Forces Are Impacting The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab, and etanercept biosimilars market is influenced by the expiry of patents for branded drugs, which opens the door for biosimilars. For example, in the United States, Hospira (a Pfizer Inc. subsidiary) obtained FDA approval for Inflectra, intended for the treatment of various autoimmune diseases including rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, after the branded drug Remicade’s patent expired. In a similar scenario, the patent for Amgen’s Enbrel expired in the EU, leading to the European Commission’s approval of Benepali, a biosimilar of Enbrel. The ending of Humira’s patent resulted in the availability of its biosimilars on the market. Hulio, the sixth biosimilar of Humira, received recent FDA approval. Thus, the end of patents for branded biologic drugs like Humira, Enbrel, and Remicade enhances the demand for adalimumab, infliximab, and etanercept biosimilars in the market.

Which Segments Define The Structure Of The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

What Strategic Shifts And Innovations Are Influencing The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading businesses in the adalimumab, infliximab, and etanercept biosimilars market are honing their focus on creating unique solutions, such as the citrate-free adalimumab, to enhance customer experiences. Citrate-free adalimumab is a version of the biological drug adalimumab, formulated without the inclusion of citrate. To illustrate, Fresenius Kabi, a Germany-domiciled pharmaceutical and medical technology company, revealed the FDA authorization for its biosimilar Idacio (adalimumab) in December 2022. It is intended for managing chronic autoimmune disorders, conforming to all allowable usages of the reference drug. Taking advantage of advanced analytical techniques, it’s been created to treat a variety of chronic diseases.

Which Firms Are Making The Biggest Impact In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Is Forecasted To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market In The Coming Years?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Adalimumab, Infliximab and Etanercept Biosimilars Market From 2025 to 2029?

The market size of adalimumab, infliximab, and etanercept biosimilars has experienced swift expansion in the past few years. The market value is anticipated to rise from $4.37 billion in 2024 to $4.96 billion in 2025, showing a compound annual growth rate (CAGR) of 13.6%. Factors contributing to growth during the historical period include an uptick in healthcare spending, regulatory adjustments, government strategies, and escalating healthcare expenses.

The market size for adalimumab, infliximab and etanercept biosimilars is anticipated to witness a substantial surge in the upcoming years. The market is predicted to reach “$7.34 billion by 2029, with a compound annual growth rate (CAGR) of 10.3%. Factors such as growing healthcare costs, an aging demographic, and improved healthcare access are anticipated to fuel this growth. Key trends during the projected period will comprise of initiatives towards new product launches, increased focus on mergers and acquisitions, strategic partnerships, and enhanced investment opportunities.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Elements Are Contributing To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

The accessibility of biosimilars in the adalimumab, infliximab, and etanercept biosimilars market has been driven by the expiration of patents on branded drugs. This includes in the United States, where Inflectra, produced by Hospira (owned by Pfizer Inc.), was sanctioned by the FDA for treating several autoimmune diseases, such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis. This followed the end of the patent on the branded drug, Remicade. In a similar case, the European Commission approved Benepali, a biosimilar of Amgen’s Enbrel, once its patent concluded in the EU. Following the termination of Humira’s patent, its biosimilars have been brought to market, with the FDA recently approving Hulio, Humira’s sixth biosimilar. Therefore, the conclusion of patents for branded biologic drugs like Humira, Enbrel, and Remicade is stimulating demand in the adalimumab, infliximab, and etanercept biosimilars market.

The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented –

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By Application: Crohn’s Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others

2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others

3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

What Long-Term Trends Are Likely To Affect The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Leading firms engaged in the adalimumab, infliximab, and etanercept biosimilars market are concentrating on the creation of novel products, such as citrate-free adalimumab, in order to offer dependable services to their clients. Citrate-free adalimumab is an iteration of the biological drug adalimumab that does not include citrate. For example, in December 2022, Fresenius Kabi, a German enterprise specializing in the manufacturing of medications and technologies related to infusion, transfusion, and clinical nutrition, received FDA approval for their biosimilar product, Idacio (adalimumab), for the control of persistent autoimmune disorders, permitting all authorized uses of the standard product. This product was developed using enhanced analytical methods for the treatment of multiple chronic diseases.

Who Are The Key Contributors To Growth In The Adalimumab, Infliximab and Etanercept Biosimilars Market?

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Region Is Projected To Lead The Adalimumab, Infliximab and Etanercept Biosimilars Market By 2025?

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3473&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model